



Strategy Certificates

Linked to the C&S Investment Strategy Basket
Issued by UBS AG



Cash settled
SVSP Product Type: Tracker Certificates (1300)
Valor: 18868755 ; ISIN: CH0188687559

Amendment as of 01 January 2019:
-New Reference Portfolio Advisor "Cité Gestion SA"
-Rebalancing / Adjustment Fee reduced to 0.05% (formerly 0.10%)

Amendment as of 1 January 2017:
-added paragraph regarding US Withholding Tax (regulation 871m)

Amendment as of 25 October 2016
-Expiration has been extended to 28 June 2022

Amendment as of 15 October 2013
-New Reference Portfolio Advisor "Ultra Finance AG" as per 15-Oct-2013 (formerly "Balius Asset Management AG")

Amendment as of 01 December 2021
-Expiration has been extended to 28 June 2027

Amendment as of 09 July 2024
-Going forward, Cura & Senectus Investment AG will replace Cité Gestion SA as new Reference Portfolio Advisor

Final Terms

This Product does not represent a participation in any of the collective investment schemes pursuant to Art. 7 ss of the Swiss Federal Act on Collective Investment Schemes (CISA) and thus does not require an authorisation of the Swiss Financial Market Supervisory Authority (FINMA). Therefore, investors in this Product are not eligible for the specific investor protection under the CISA.

1. Description of the Product

Information on Underlying

The C&S Investment Strategy Basket enables the investor to participate at the net total return (capital appreciation and net dividends) of a selected basket of shares. The strategy focuses on mid and large capitalization companies rebalanced by the Reference-Portfolio Advisor.

Underlying(s)

Description

The Strategy Basket (the "Reference-Portfolio")

The C&S Investment Strategy Basket (the "Reference-Portfolio") is a notional USD ("USD") denominated actively managed Reference-Portfolio, created and maintained by Cura & Senectus Investment AG Genève (the "Reference-Portfolio Advisor"). The Reference-Portfolio aims to replicate (i) the performance of a basket of mid and large capitalization stocks (the "Constituents"), and (ii) from time to time, a cash position (the "Cash Position", which together with the Constituents shall be referred to as the "Reference-Portfolio Components"), less fees and expenses. The Reference-Portfolio Advisor maintains the Reference-Portfolio in accordance with the attached Reference-Portfolio Guidelines (Annex).

Product Details

Security Numbers	Valor: 18868755 / ISIN: CH0188687559 / WKN: UU2GJ2
Issue Size	Up to 200'000 Units (with reopening clause)
Issue Price	USD 100.00

Contact: UBS AG, P.O. Box, 8098 Zurich

Institutional Investors: 41-44-239 14 66*
Private Investors: derivatives@ubs.com

Internet: www.ubs.com/keyinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

Settlement Currency	USD
Currency Treatment	The Reference-Portfolio can invest in and be exposed to Reference-Portfolio Components denominated in currencies other than the Settlement Currency. The currency risk is not hedged.

Dates

Launch Date	28 June 2012
Pricing Date ("Pricing")	28 June 2012
Issue Date / Payment Date	05 July 2012
Last Trading Day	28 June 2027
Expiration Date	28 June 2027 (subject to Market Disruption Events, Early Termination and Unwind Disruption provisions), extendable at the option of the Issuer for additional 5 years periods, on a rolling basis, with a notice period of 180 calendar days. In case this day is not a Business Day, the next following Business day will apply.
Redemption Date	5 Business Days following the Expiration Date (currently expected to be 05 July 2022) or the Early Termination Date (as applicable) (in any case subject to Market Disruption Event provisions).
Closing Date (for Swiss tax purposes)	1 January, for the first time 1 January 2013

Redemption

Redemption Amount	The Investor is entitled to receive from the Issuer on the Redemption Date an amount in the Settlement Currency equal to the Reference-Portfolio Level on the Expiration Date or the Early Termination Date, as applicable, as calculated by the Calculation Agent.
-------------------	---

In the event that a notional investor (in the same position as the Issuer) would be unable to unwind its investments in the Reference-Portfolio Constituents by the Expiration Date or the Early Termination Date (as applicable) (such event a "**Unwind Disruption**"), the Issuer reserves the right to extend the Expiration Date or Early Termination Date to such date where a notional investor in the Reference-Portfolio Components is able to fully unwind the Reference-Portfolio Components in cash.

For the avoidance of doubt, the Redemption Amount in case of an Early Termination may include (inter alia) any costs arising from the Issuer unwinding any hedges in connection with the Product.

Please note that the Redemption Amount may be less than the initially invested capital.

Early Termination by Issuer	The Issuer is entitled to early terminate the Product in full subject to the following notice period: Quarterly, i.e. as of each 31 March, 30 June, 30 September and 31 December (the " Early Termination Date ") subject to at least 45 Business Days prior notice being given to the Investors. The first possible Early Redemption Date will be 30 September 2012.
-----------------------------	---

There is no Early Termination right for the Investor.

Contact: UBS AG, P.O. Box, 8098 Zurich
Institutional Investors: +41-44-239 68 00*
Private Investors: derivatives@ubs.com Internet: www.ubs.com/keyinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

UBS Investment Bank is a business division of UBS AG

Reference-Portfolio Level	Sum of all Reference-Portfolio Components taking into consideration their respective weightings whereby the Equity Position is valued at the closing price published by the primary exchange of the respective Stocks. The calculation also takes into account the effect of all fees and costs associated with the Reference Portfolio. The Reference-Portfolio Level is calculated for each Business Day by the Calculation Agent on the next Business Day.
Dividends	<p>Any amounts reflecting net dividends of the Reference-Portfolio Constituents will be added to the cash position of the Reference-Portfolio.</p> <p>In respect of U.S. equity securities, for purposes of determining the amount of a dividend treated as notionally reinvested, such amount shall not be treated as reduced by the withholding tax imposed on dividends by Section 871(a) or 881(a) of the US Internal Revenue Code but shall instead be reduced by the 30% withholding tax imposed on dividend equivalents by Section 871(m) of the U.S. Internal Revenue Code of 1986, as amended.</p>
Automatic Redemption Amount	<p>An amount in USD based on the weighted average of the Reference Portfolio Level over the last five Business Days prior to and including the date on which the Stop Loss Event occurred, as calculated by the Calculation Agent.</p> <p>For the avoidance of doubt, the Automatic Redemption Amount may include (inter alia) any costs arising from the Issuer unwinding any hedges in connection with the Product.</p> <p>Please note that the Automatic Redemption Amount may be less than the initially invested capital.</p>

Product Structure

The Product allows for participation in the performance of the Reference-Portfolio. The Reference-Portfolio is a notional actively managed portfolio based on a basket of stocks and Cash, maintained by the Reference-Portfolio Advisor according to the attached Reference-Portfolio Guidelines. The Reference-Portfolio aims to replicate the performance level of a basket of stocks and, from time to time a cash position, less fees and expenses. Any amounts reflecting net dividends of the Reference-Portfolio Constituents will be re-invested into the Reference-Portfolio.

General Information

Issuer	UBS AG, London
Issuer Rating	A2 Moody's / A S&P's / A Fitch
Lead Manager	UBS AG, London (UBS Investment Bank)
Calculation Agent	UBS AG, London Branch
Paying Agent	UBS AG, London Branch
Reference-Portfolio Advisor	Cura & Senectus Investment AG
Business Days	Any days in which banks in London, Frankfurt a.M., Zurich, Hong Kong and New York are open for business.
Liquidity	UBS intends to offer daily bid/offer prices depending on size, market conditions such as liquidity in the markets of the Reference-Portfolio Components.
Reference-Portfolio fees (calculated daily)	Quarterly fee of 0.40% (1.60% per year) of the Reference-Portfolio Level accrued on a daily basis, plus (i) certain expenses commonly to be associated with establishing, maintaining and rebalancing a portfolio similar to the notional portfolio mirrored by the Reference-Portfolio and (ii) the Adjustment Fee, charged by the Calculation Agent and deducted from the Reference-Portfolio Level. The dates of the 0.40% fee deduction are 31 March, 30 June, 30 September and 31 December (in case any of the dates is not a Business Day, the next following Business Day will apply). A part of the Reference-Portfolio Fee will be used to compensate the Reference Portfolio Advisor.

Contact: UBS AG, P.O. Box, 8098 Zurich

Institutional Investors: +41-44-239 68 00*

Private Investors: derivatives@ubs.com

Internet: www.ubs.com/keyinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

UBS Investment Bank is a business division of UBS AG

Reference-Portfolio Performance Fee (high watermark) (calculated quarterly)

If the performance of the Reference Portfolio is above the highest previous end of quarter NAV (high watermark), a quarterly fee of 15% on the quarterly outperformance mirrored by the Reference-Portfolio Level - the SPR 1500 Composite Index (Bloomberg: SPR Index) from the respective initial and final levels of each quarter and after deduction of the Reference-Portfolio Fee, is charged by the Calculation Agent and deducted from the Reference-Portfolio Level. The dates of the Performance Fee deduction are 31 March, 30 June, 30 September and 31 December (in case any of the dates is not a Business Day, the next following Business Day will apply) (the "**Performance Fee Deduction Dates**"). **The entire amount of the Reference-Portfolio Performance Fee will be used to compensate the Reference-Portfolio Advisor.**

The Performance Fee with high watermark is calculated as follows:

If $RPL(t) - SPR(t) > 0$ and if $RPL(t) > RPL(t-Q_{max})$, the Reference-Portfolio Advisor receives the Performance Fee (t) of $15\% \times (RPL(t) - SPR(t))$

Where

Performance Fee (t) means Reference-Portfolio Performance Fee on the Performance Fee Deduction Date (t).

SPR (t) means the S&P 1500 Composite Index (SPR Index) closing level of the respective day - the closing level of the previous quarter quoted in %.

RPL (t) means the Reference-Portfolio Level after the deduction of the 0.40% for the current quarter on the Performance Fee Deduction Date (t) - the closing level of the previous quarter quoted in %.

RPL (t-Q_{max}) means the highest of the Reference-Portfolio Levels observed on all of the previous Performance Fee Deduction Dates (including the Issue Date) versus the initial Reference Portfolio Level quoted in %.

Rebalancing

Rebalancing means any change in the Reference-Portfolio Components by the Reference-Portfolio Advisor after the Issue Date. The Calculation Agent has the right to reject Rebalancings under specific circumstances. The expected number of Rebalancings per year is 52.

In case of a Rebalancing, secondary market trading of the Product will be suspended until completion of the Rebalancing.

Rebalancing / Adjustment Fee

An Adjustment Fee is levied for each adjustment made in the Reference-Portfolio, and represents a percentage of the notional volume of each of the purchase and/or sale of a Constituent. The Adjustment Fee equals 0.05% as at the Launch Date. The Adjustment Fee can be adjusted by the Reference-Portfolio Calculation Agent, but may not amount to more than 0.25%.

Minimum Investment

1 Unit(s)

Minimum Trading Lot

1 Unit(s)

Clearing

SIX SIS, Euroclear, Clearstream (registered as intermediated securities with SIX SIS AG, in Switzerland)

Form of deed

Uncertificated Securitites

Governing Law / Jurisdiction

Switzerland / Zurich

Adjustments

The terms of the Product may be subject to adjustments during its lifetime. Detailed information on such adjustments is to be found in the Product Documentation.

Public Offering

Switzerland

Contact: UBS AG, P.O. Box, 8098 Zurich

Institutional Investors: +41-44-239 68 00*

Private Investors: derivatives@ubs.com

Internet: www.ubs.com/keyinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

UBS Investment Bank is a business division of UBS AG

Tax Treatment Switzerland

Swiss Federal Stamp Duty	The product is treated as analogous to a share in a foreign investment fund. Therefore, primary and secondary market transactions are in principle subject to Swiss Federal Stamp Duty.
Swiss Federal Income Tax	The taxable income and capital gains/losses will be kept apart and will be reported to the Swiss Federal Tax Administration annually. Taxable income is subject to Swiss Federal, cantonal and communal income tax.
Swiss Withholding Tax	The product is not subject to the Swiss withholding tax.
EU Savings Tax Treatment	For Swiss paying agents, the product is not subject to the EU Savings tax.

The tax information only provides a general overview of the potential tax consequences linked to this product at the time of issue. Tax laws and tax doctrine may change, possibly with retroactive effect.

Product Documentation

The Final Terms together with the 'General Terms and Conditions for Structured Products on Equity, Commodity and Index Underlyings', as amended from time to time ("**General Terms and Conditions**") shall form the entire documentation for this Product ("**Product Documentation**"), and accordingly the Final Terms should always be read together with the General Terms and Conditions. Definitions used in the Final Terms, but not defined therein shall have the meaning given to them in the General Terms and Conditions. Furthermore, the Final Terms shall serve as and fulfil the requirements of a 'Simplified Prospectus' in accordance with Art. 5 of the Swiss Federal Act on Collective Investment Schemes (CISA). In the event that the Product is listed (see above item 'Listing' under 'General Information'), the Product Documentation will be amended in accordance with the listing requirements of the relevant Exchange.

During the whole term of this Product, the Product Documentation can be ordered free of charge from the Lead Manager at P.O. Box, CH-8098 Zurich (Switzerland), via telephone (+41-(0)44-239 47 03), fax (+41-(0)44-239 69 14) or via e-mail (swiss-prospectus@ubs.com). In addition, the Product Documentation is available on the internet at www.ubs.com/keyinvest.

Notices in connection with this Product shall be validly given by publication in electronic media such as Reuters and/or Investdata. In addition, any changes with regard to the terms of this Product shall be published on the internet at www.ubs.com/keyinvest.

Classification

This Product does not represent a participation in any of the collective investment schemes pursuant to Art. 7 ss of the Swiss Federal Act on Collective Investment Schemes (CISA) and thus does not require an authorisation of the Swiss Financial Market Supervisory Authority (FINMA). Therefore, investors in this Product are not eligible for the specific investor protection under the CISA.

Furthermore, this Product does not benefit from any depositor protection under Art. 37b under the Swiss Federal Law on Banks and Savings Banks (Banking Act) or other forms of deposit insurance under any other law as might be applicable to this Product.

Prudential Supervision

UBS AG is authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA). In addition, its London Branch is authorised and regulated by the Financial Services Authority (FSA) and its Jersey Branch by the Jersey Financial Services Commission (JFSC).

2. Prospects of Profits and Losses

Contact: UBS AG, P.O. Box, 8098 Zurich
Institutional Investors: +41-44-239 77 60*
Private Investors: derivatives@ubs.com Internet: www.ubs.com/keyinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

Market Expectation	Investor expects the positive performance in a basket of stocks over the life of the Product.
Risk Tolerance	<p>Investors should be experienced investors and familiar with both derivative products and the stock / commodity markets.</p> <p>The investors must be willing to make an investment that is fully exposed to the performance of the underlying, meaning that Investors might lose their whole investment in the Product in the worst case.</p> <p>The Reference-Portfolio may contain Reference-Portfolio Components denominated in currencies other than the Settlement Currency. The currency risk is not hedged.</p>
Profit Potential	<p>The Product allows for participation in positive performance of the Underlying, as adjusted by various fees and expenses as described in more detail above.</p> <p>Furthermore, if prior to the Expiration Date the Investor decides to buy/sell the Product under the Secondary Market terms (as detailed above), the Investor may also be exposed to any funding costs of the Issuer (including, but not limited to, any internal funding costs whether caused by changes in UBS's credit status or otherwise) in relation to the Product.</p>
Loss Potential	<p>The Investors may lose some or all of the investment as they are exposed to the negative performance of the Underlying.</p> <p>The Issuer is entitled to redeem the Product early.</p>

3. Significant Risks for Investors

For product specific risks please see above (2. Prospects of Profits and Losses)

Risk Factors relating to the Issuer

In addition to the market risk with regard to the development of the Underlying, each Investor bears the general risk that the financial situation of the Issuer could deteriorate. The Products constitute immediate, unsecured and unsubordinated obligations of the Issuer, which, particularly in case of insolvency of the Issuer, rank pari passu with each and all other current and future unsecured and unsubordinated obligations of the Issuer, with the exception of those that have priority due to mandatory statutory provisions. The general assessment of the Issuer's creditworthiness may affect the value of the Products. This assessment generally depends on the ratings assigned to the Issuer or its affiliated companies by rating agencies such as Moody's, Fitch and Standard & Poor's.

The Issuer Ratings indicated in this document reflect the situation at the time of issuance and may be subject to changes. The actual Issuer Ratings at any given time can be seen on the Issuer's website (www.ubs.com) under "Analysts & Investors".

Secondary Market

The Issuer or the Lead Manager, as applicable, intends, under normal market conditions, to provide bid and offer prices for this Product on a regular basis. However, the Issuer or the Lead Manager, as applicable, makes no firm commitment to provide liquidity by means of bid and offer prices for this Product, and assumes no legal obligation to quote any such prices or with respect to the level or determination of such prices. Potential Investors therefore should not rely on the ability to sell this Product at a specific time or at a specific price.

In special market situations, where the Issuer is completely unable to enter into hedging transactions, or where such transactions are very difficult to enter into, the spread between the bid and offer prices may be temporarily expanded, in order to limit the economic risks of the Issuer.

Market Risk

Contact: UBS AG, P.O. Box, 8098 Zurich
Institutional Investors: +41-44-239 77 60*
Private Investors: derivatives@ubs.com Internet: www.ubs.com/keyinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

The investor is exposed to market disruption events (such as trading disruption, exchange disruption and early closure of the relevant exchange), adjustments and early termination which could have an impact on the redemption amount through delay in payment or change in value. For a detailed description of such events and their effects please read the Final Terms and the base prospectus (Base Prospectus Equity).

Important Information

This information is communicated by UBS AG and/or its affiliates ("UBS"). UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the transaction to which this document relates. UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this document. UBS' trading and/or hedging activities related to this transaction may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier is crossed. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available.

In certain circumstances UBS sells this Product to dealers and other financial institutions at a discount to the issue price or rebates to them for their account some proportion of the issue price. Further information is available on request.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in any transaction.

This document should not be construed as an offer, personal recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The terms of any investment will be exclusively subject to the detailed provisions, including risk considerations, contained in the Information Memorandum, Prospectus or other issuer documentation for the issue of the Products/Notes (the "Prospectus").

UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS' prior written permission.

No action has been or will be taken in any jurisdiction that would permit a public offering of the Products described herein, save where explicitly stated in the Product Documentation. The Products must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.

There is a possibility that costs, including taxes, related to transactions in connection with this Product may arise for the Investor that are not paid by UBS or imposed by it.

Contact: UBS AG, P.O. Box, 8098 Zurich
Institutional Investors: +41-44-239 77 60*
Private Investors: derivatives@ubs.com Internet: www.ubs.com/keyinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

Selling Restrictions

Any Products purchased by any person for resale may not be offered in any jurisdiction in circumstances which would result in the Issuer being obliged to register any further documentation relating to this Product in such jurisdiction.

The restrictions listed below must not be taken as definitive guidance as to whether this Product can be sold in a jurisdiction. Additional restrictions on offering, selling or holding of this Product may apply in other jurisdictions. Investors in this Product should seek specific advice before on-selling this Product.

Europe - Any public offer of this Product within a EEA jurisdiction (EU member states plus Norway, Iceland and Liechtenstein) shall only be possible if compliant with the requirements of the EUPD and with the law of that jurisdiction.

If the prospectus either does not qualify as a prospectus published in accordance with the requirements of the EUPD or is not filed with or notified to the relevant Financial Supervisory Authority, this Product may not be offered or sold in EEA jurisdictions other than 1) in minimum denominations of, or total consideration per investor of at least, EUR 50,000 (or equivalent in other currencies), provided that the offer is only being made in one or more EEA jurisdiction that will not, before the end of the offer period for the Notes, have implemented the provision under the Directive 2010/73/EU (the "PD Amending Directive") that increases this minimum denomination (or total consideration per investor) to EUR 100,000; or 2) only to Qualified Investors; and/or (aggregated for all distributors) to less than 100 or, if the relevant EEA jurisdiction has implemented the relevant provision of the 2010 PD Amending Directive, 150 natural or legal persons that are not Qualified Investors per EEA jurisdiction. "Qualified Investors" are persons or entities as defined in the Prospectus Directive.

For information on public offering in EEA jurisdictions please see under section "General Information" above.

Hong Kong – Each purchaser has represented and agreed that it has not issued or had in its possession for the purposes of issue, and will not issue or have in its possession for the purposes of issue, whether in Hong Kong or elsewhere, any advertisement, invitation or document relating to the Products, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to Products which are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance.

This is a structured product which involves derivatives. Do not invest in it unless you fully understand and are willing to assume the risks associated with it. If you are in any doubt about the risks involved in the product, you may clarify with the intermediary or seek independent professional advice.

Singapore - This document has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this document and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of this Product may not be circulated or distributed, nor may this Product be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act (Cap. 289) of Singapore ("SFA"), (ii) to a relevant person pursuant to Section 275(1), or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275, of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

Where this Product is subscribed or purchased under Section 275 of the SFA by a relevant person which is:

- (a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or
 - (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,
- securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities pursuant of an offer made under Section 275 of the SFA except:
- (1) to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section 276 (4)(i)(B) of the SFA;
 - (2) where no consideration is or will be given for the transfer;
 - (3) where the transfer is by operation of law; or
 - (4) as specified in Section 276 (7) of the SFA.

UK – For the purpose of non-discretionary accounts, this Product should not be sold with a consideration of less than 100,000 EUR or equivalent.

USA - This Product may not be sold or offered within the United States or to U.S. persons.

Contact: UBS AG, P.O. Box, 8098 Zurich
Institutional Investors: +41-44-239 77 60*
Private Investors: derivatives@ubs.com Internet: www.ubs.com/keyinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

Annex

Reference-Portfolio Guidelines

The C&S Investment Strategy Basket

The C&S Investment Strategy Basket (the "**Reference-Portfolio**") is a notional USD ("USD") denominated actively managed Reference-Portfolio, created and maintained by Cura & Senectus Investment AG e (the "**Reference-Portfolio Advisor**"). The Reference-Portfolio aims to replicate (i) the performance of a basket of mid and large capitalization stocks ("**Constituents**"), and (ii) from time to time, a cash position (the "**Cash Position**", which together with the Constituents shall be referred to as the "**Reference-Portfolio Components**"), less fees and expenses.

The Reference-Portfolio Components are selected by the Reference-Portfolio Advisor in accordance with the following guidelines (the "Reference-Portfolio Guidelines"):

1. Only shares (the "Investment Universe") with sufficient liquidity may be incorporated as Reference-Portfolio Constituents in the Reference-Portfolio ("Eligible Stocks")
2. The Cash Position may at no time exceed 50% of the value of the Reference-Portfolio. No interest will be paid on the Cash Position.

In case of a rebalancing the theoretical volume of a buy or sell order for a Constituent is limited to 200% of the average traded daily volume of that Constituent. A rebalancing may happen at the discretion of the Reference-Portfolio Advisor. The Calculation Agent has the right to reject constituents that form part of a Rebalancing. The theoretical volume is defined as the number of outstanding Certificates multiplied by the Reference-Portfolio Level (using a reasonable foreign exchange rate to convert into the currency of the Constituent) and multiplied by the change in the percentage weight of the Constituent. The average traded daily volume is defined as the 30 Day average trading turnover. The expected number of Rebalancings per year is 52.

At any time, the Reference-Portfolio may reflect a cash position which mirrors the holding of cash, money market instruments or cash obligations (the "Cash Position").

A Quarterly fee of 0.40% (1.60% per year) of the Reference-Portfolio Level accrued on a daily basis, plus (i) certain expenses commonly to be associated with establishing, maintaining and rebalancing a portfolio similar to the notional portfolio mirrored by the Reference-Portfolio and (ii) the Adjustment Fee, charged by the Calculation Agent and deducted from the Reference-Portfolio Level. The dates of the 0.40% fee deduction are 31 March, 30 June, 30 September and 31 December (in case any of the dates is not a Business Day, the next following Business Day will apply). A part of the Reference-Portfolio Fee will be used to compensate the Reference Portfolio Advisor.

If the performance of the Reference Portfolio is above the highest previous end of quarter NAV (high watermark), a quarterly fee of 15% on the quarterly outperformance mirrored by the Reference-Portfolio Level - the SPR 1500 Composite Index (Bloomberg: SPR Index) from the respective initial and final levels of each quarter and after deduction of the Reference-Portfolio Fee, is charged by the Calculation Agent and deducted from the Reference-Portfolio Level.

An Adjustment Fee is levied for each adjustment made in the Reference-Portfolio, and represents a percentage of the notional volume of each of the purchase and/or sale of an Eligible Stock. The Adjustment Fee was set by the Reference-Portfolio Advisor in accordance with the Reference-Portfolio Calculation Agent at 0.10% as at the Launch Date. The Adjustment Fee can be adjusted by the Reference-Portfolio Calculation Agent, but may not amount to more than 0.25%. The Reference-Portfolio Fee is accrued on a daily basis and paid on a quarterly basis, on 31 March, 30 June, 30 September and 31 December should any of these dates fall on a day which is not a Business Day, the Fee is paid on the next Business Day).

The Reference-Portfolio is denominated in USD, while the Constituents, notionally comprised in the Reference-Portfolio, might be denominated in other currencies than USD. In order to appropriately reflect the performance of the Constituents in the determination of the value of the Reference-Portfolio, the value of the Constituents denominated in other currencies than USD is expressed in USD. The exchange rate equals the currently prevailing exchange rate. The exchange-rate risk is not mitigated.

The above Universe can be amended in agreement between the Calculation Agent and the Reference-Portfolio Advisor. The Calculation Agent has the right to reject Constituents that form part of a Rebalancing.

Contact: UBS AG, P.O. Box, 8098 Zurich
Institutional Investors: +41-44-239 77 60*
Private Investors: derivatives@ubs.com Internet: www.ubs.com/keyinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

Name	Bloomberg Code	Initial weight	Spot Level	No. Of Shares in Reference-Portfolio
Alliance Data Sys Corp	ADS US Equity	3.00%	132.6954	0.0226082
Altria Group Inc	MO US Equity	4.00%	34.0843	0.1173561
Amgen Inc	AMGN VX Equity	5.00%	71.5317	0.0698991
Auxilium Pharmaceuticals	AUXL US Equity	4.00%	26.5978	0.1503884
Biogen Idec Inc	BIIB US Equity	5.00%	140.3011	0.0356376
Concur Technologies Inc	CNQR US Equity	4.00%	65.7115	0.0608721
Cyberonics Inc	CYBX US Equity	4.00%	44.3965	0.0900972
Davita Inc	DVA US Equity	4.00%	96.6518	0.0413857
Ebay Inc	Ebay US Equity	4.00%	40.7263	0.0982166
Edwards Lifesciences Cp	EW US Equity	3.00%	101.2052	0.0296427
Hershey Company	HSY US Equity	4.00%	69.9222	0.0572064
M W I Veterinary Supply	MWIV US Equity	4.00%	101.5227	0.0394001
Mckesson Corp	MCK US Equity	4.00%	93.2537	0.0428937
Merck & Co	MRK US Equity	4.00%	40.6239	0.0984642
P P G Industries	PPG US Equity	4.00%	103.5072	0.0386447
Questcor Pharmaceuticals	QCOR US Equity	3.00%	51.7996	0.0579155
Ryland Group	RYL US Equity	4.00%	24.9983	0.1600109
T J X Cos Inc	TJX US Equity	3.00%	41.5934	0.0721268
T W Telecom Inc	TWTC US Equity	4.00%	25.3976	0.1574952
Texas Capital Bancshares	TCBI US Equity	4.00%	40.2933	0.0992721
U S Bancorp Inc	USB US Equity	4.00%	31.5208	0.1269003
Verisign Inc	VRSN US Equity	4.00%	42.544	0.0940203
Visa Inc Cl A	V US Equity	3.00%	121.4495	0.0247016
Vitamin Shoppe Inc	VSI US Equity	5.00%	52.5073	0.0952249
Wal-Mart Stores	WMT US Equity	4.00%	68.2842	0.0585787
Cash		2.00%		

Contact: UBS AG, P.O. Box, 8098 Zurich

Institutional Investors: +41-44-239 77 60*
Private Investors: derivatives@ubs.com

Internet: www.ubs.com/keyinvest

Please note that calls made to the numbers marked with an asterisk (*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.